Mary Gardner, CEO and Founder of DelNova Inc., and former Director of Technology Assessment, Hospira, a Pfizer company (~11 yrs), has dedicated her career in the area of innovation and commercialization for the pharma/biotech & life science industry. DelNova (founded in 2016) is focused on applying drug delivery expertise for superior therapeutic benefit. Mary is the inventor, of a novel product candidate, ReVivox™ now under development.
At Hospira/Pfizer, Mary was responsible for the front end of innovation, including supporting business development via the sourcing & evaluation of external new technology and product opportunities to generate future topline growth in healthcare products (pharmaceuticals, drug delivery and medical devices). Is experienced in the healthcare & biotechnology industries including positions in consulting, process design engineering and project management.
Prior to joining Hospira, Mary led the Business Development office of The Lawson Health Research Institute & London Health Sciences Centre, London Ontario. Here she was responsible for managing the IP portfolio, technology transfer & spin-off companies created from innovations arising out of leading Canadian teaching hospitals.
Education; MBA (finance& innovation) from McMaster University, Hamilton and a BEngSc (Chemical & Biochemical) from the University of Western Ontario, London, Canada and is a Certified Licensing Professional (CLP).